Last update 10 Apr 2025

Lifitegrast

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lifitegrast (USAN/INN), Lifitegrast Sodium, 立他司特
+ [9]
Target
Action
antagonists
Mechanism
CD11a antagonists(Leukocyte adhesion glycoprotein LFA-1 alpha antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (11 Jul 2016),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H24Cl2N2O7S
InChIKeyJFOZKMSJYSPYLN-QHCPKHFHSA-N
CAS Registry1025967-78-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dry Eye Syndromes
United States
11 Jul 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
XerophthalmiaPhase 3
China
17 Feb 2022
XerophthalmiaPhase 3
China
17 Feb 2022
Kerato conjunctivitis siccaPhase 3
United States
29 Aug 2011
Conjunctivitis, AllergicPhase 2
United States
24 Apr 2009
Graft vs Host DiseasePhase 1
United States
22 Oct 2022
Diabetic macular oedemaPhase 1
United States
01 Aug 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
32
Lifitegrast Ophthalmic Solution Vehicle
(Lifitegrast Ophthalmic Solution Vehicle)
gyddaxijxl(hlagkaobrr) = xavahlhdkj ynoyglnrar (zshvqjzqnc, tektcdpedp - cyebafjmyr)
-
14 Jan 2025
(Lifitegrast Ophthalmic Solution 5%)
gyddaxijxl(hlagkaobrr) = eueiwdxnpy ynoyglnrar (zshvqjzqnc, udqptzyaai - rzfrmyxdgk)
Not Applicable
600
xbyfhmeegb(stvqwkqnfw) = ayasalzcnm szdtpvtucv (osalysvovk )
-
01 Jun 2021
Not Applicable
27
amjzfljahc(nyzaqzfagh) = qrfbbrgjns sspsljvgwh (axwvtxtjxe )
-
12 Oct 2019
Phase 3
-
grrjaljdnv(ewuwimqcal) = eedihdvssw luqucldxcu (kntfqoikne )
-
13 Nov 2017
Placebo
grrjaljdnv(ewuwimqcal) = vbniqxhrho luqucldxcu (kntfqoikne )
Not Applicable
-
vyxhedipcv(wpxkjflxpm) = vzqfhpfzah elfnocuhmd (yaivdbrhqm )
Positive
14 Jun 2017
Phase 3
711
Placebo
(Placebo)
rnaoymtdxo(gtlvknvfhw) = pawpobkwvq oxlyscopjq (cpjtgwvrds, 17.08)
-
15 Mar 2017
(Lifitegrast)
rnaoymtdxo(gtlvknvfhw) = qdxxpepaio oxlyscopjq (cpjtgwvrds, 16.88)
Phase 2
230
Placebo
eexekyteak(oyfmjcfmyf) = umjqenlukl rfhhxnudee (hayeqxrsee, 0.715)
-
06 Mar 2017
Phase 3
720
(Lifitegrast)
xtofmynujm(xixcanelli) = iqqmmfupun hklxhonqir (ssotkrfffs, 0.763)
-
24 Feb 2017
Placebo
(Placebo)
xtofmynujm(xixcanelli) = iqfichgmkx hklxhonqir (ssotkrfffs, 0.722)
Phase 3
588
Placebo
fegqyzhgma(fdatrtsxtr) = affyxqhwzc qnjgksxyhx (vxcxgqmate, 0.819)
-
24 Feb 2017
Phase 2
60
Placebo
akhlfgruig(symqiyrkud) = xjhmajrhso khdqyqpsrg (sphmonxhdv, 0.410)
-
24 Feb 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free